Trials / Completed
CompletedNCT00456027
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
A Placebo-Controlled Study to Investigate the Impact of Diamyd® on the Diabetes Status of Patients With LADA (Latent Autoimmune Diabetes in Adult)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Diamyd Therapeutics AB · Industry
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune Diabetes in Adult (LADA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhGAD65 formulated in Alhydrogel® (Diamyd®) | 20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2008-03-01
- Completion
- 2008-04-01
- First posted
- 2007-04-04
- Last updated
- 2011-06-10
Locations
17 sites across 1 country: Sweden
Source: ClinicalTrials.gov record NCT00456027. Inclusion in this directory is not an endorsement.